EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions

Bisheng Cheng, Lanqi Gong, Zongwei Wang, Peidan Peng, Kewei Xu, Hai Huang, Peng Wu

MedComm · 2026-04 · 7 (4)

DOI: 10.1002/mco2.70699 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 30.03.2026. Verfasst von Bisheng Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Nanfang Hospital Southern Medical University Guangzhou China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) have emerged as a major therapeutic modality in oncology, enabling the targeted delivery of highly potent cytotoxic agents while expanding the therapeutic window in solid tumors. Recent clinical successes across breast, lung, and genitourinary cancers have highlighted that ADC efficacy is governed not only by target expression, but also by the integrated optimization of antibody engineering, linker chemistry, payload selection, and tumor‐specific biology. In this review, we summarize the fundamental principles underpinning ADC design, including antibody format and Fc engineering, linker stability, payload classes, drug‐to‐antibody ratio optimization, and the bystander effect. We then discuss tumor antigen biology and target landscapes across solid tumors, with particular emphasis on how antigen density, heterogeneity, internalization kinetics, and intracellular trafficking shape clinical activity. Uro‐oncological malignancies—especially urothelial carcinoma—are presented as a clinically advanced and instructive paradigm for ADC development. Experience from these tumors illustrates both the opportunities and limitations of ADC therapy, including mechanisms of response and resistance, biomarker‐driven patient selection, rational combination strategies, and safety management in real‐world practice. Finally, we provide a forward‐looking perspective on next‐generation ADC development, highlighting emerging conjugation technologies, bispecific and conditionally activated ADCs, strategies to overcome resistance, and evolving clinical trial designs. By integrating engineering principles with tumor biology and clinical execution, this review aims to offer a translational framework to guide the future development and implementation of ADCs across oncology.

Schlagwörter

Stichwörter der Autor:innen

antibody–drug conjugatesdrug resistancetherapeutic indextumor microenvironment

Autor:innen und Institutionen

  • Department of Urology Nanfang Hospital Southern Medical University Guangzhou China.
  • Department of Surgery Division of Urology, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA.
  • Department of Clinical Oncology, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong, SAR China.
  • Department of Clinical Oncology The University of Hong Kong-Shenzhen Hospital Shenzhen China.
  • Department of Urology Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University Guangzhou China.
  • Southern Medical University Guangzhou China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Cheng, B., Gong, L., Wang, Z., Peng, P., Xu, K., Huang, H., & Wu, P. (2026). Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions. MedComm, 7(4). https://doi.org/10.1002/mco2.70699

Vancouver

Cheng B, Gong L, Wang Z, Peng P, Xu K, Huang H, et al. Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions. MedComm. 2026;7(4). doi:10.1002/mco2.70699

BibTeX
@article{Cheng2026,
  author = {Cheng, Bisheng and Gong, Lanqi and Wang, Zongwei and Peng, Peidan and Xu, Kewei and Huang, Hai and Wu, Peng},
  title = {Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions},
  journal = {MedComm},
  year = {2026},
  volume = {7},
  number = {4},
  doi = {10.1002/mco2.70699}
}
Kostenlos starten →